Related Experiment Video
Updated: Mar 27, 2026
Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing
Published on: September 25, 2011
Epidermal Growth Factor Receptor Inconsistency by Immunohistochemistry Method Using Different Monoclonal Antibodies
Background:
Targeted therapy is typically used to treat colorectal cancer (CRC). The epidermal growth factor receptor (EGFR) was recognized as a potential therapeutic target. Does the EGFR protein express consistently using different monoclonal antibodies in clinics?
Methods:
One hundred and sixty-four patients (mean age 61.80 ± 12.78 years) who suffered from CRC were selected at Mackay Memorial Hospital in Taiwan. Formalin-fixed and paraffin-embedded tissue sections from all patients were tested simultaneously using two commercial antibodies, Dako-EGFR (mouse monoclonal anti-EGFR clone 2-18C9, pharmDx) and NCL-EGFR (NCL-EGFR-384, Novocastra) monoclonal antibodies, to study the commutability or equality of the qualities of EGFR expression by standard immunohistochemistry (IHC) procedures.
Results:
The EGFR expressions that were obtained by IHC staining using different monoclonal antibodies with Dako-EGFR (46.95%) and NCL-EGFR (32.32%) were fairly concordant.
Conclusions:
Although IHC is a convenient and feasible method for detecting the expression of EGFR, it yields controversial staining results concerning EGFR expression using various commercial antibodies in a CRC tumor section.
Insights
Colorectal cancer (CRC) treatment targets epidermal growth factor receptor (EGFR). Immunohistochemistry (IHC) for EGFR expression in CRC tumors showed fair concordance between different antibodies, but results remain controversial.
Area of Science:
- Oncology
- Immunohistochemistry
- Molecular Diagnostics
Background:
- Colorectal cancer (CRC) management often involves targeted therapy.
- Epidermal growth factor receptor (EGFR) is a key therapeutic target in CRC.
- Consistent EGFR protein expression assessment is crucial for effective treatment.
Purpose of the Study:
- To evaluate the consistency of epidermal growth factor receptor (EGFR) protein expression in colorectal cancer (CRC) tissues.
- To compare the performance of two different commercial monoclonal antibodies for EGFR detection using immunohistochemistry (IHC).
Main Methods:
- One hundred sixty-four CRC patients' tissue samples were analyzed.
- Standard immunohistochemistry (IHC) procedures were employed.
- Two distinct commercial antibodies, Dako-EGFR and NCL-EGFR, were used simultaneously for EGFR detection.
Main Results:
- EGFR expression levels detected by Dako-EGFR antibody were 46.95%.
- EGFR expression levels detected by NCL-EGFR antibody were 32.32%.
- A fair concordance was observed between the two antibodies in EGFR expression detection.
Conclusions:
- Immunohistochemistry (IHC) is a feasible method for detecting EGFR expression in CRC.
- The use of different commercial antibodies for EGFR detection can lead to controversial staining results.
- Standardization of antibody selection is important for reliable EGFR assessment in CRC diagnostics.
More Related Videos
08:28Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
06:51Confocal Microscopy Reveals Cell Surface Receptor Aggregation Through Image Correlation Spectroscopy
Published on: August 2, 2018
